Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
80 hedge funds and large institutions have $397M invested in Adaptimmune Therapeutics in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 24 reducing their positions, and 27 closing their positions.
1,555% more call options, than puts
Call options by funds: $2.25M | Put options by funds: $136K
13% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 24
0.55% less ownership
Funds ownership: 11.57% → 11.02% (-0.55%)
14% less funds holding
Funds holding: 93 → 80 (-13)
48% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 27
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
55% less capital invested
Capital invested by funds: $888M → $397M (-$491M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$50.1M |
| 2 |
O
OrbiMed
New York
|
+$5.05M |
| 3 |
Man Group
London,
United Kingdom
|
+$4.76M |
| 4 |
JP Morgan Chase
New York
|
+$2.12M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$2.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$9.47M |
| 2 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
-$7.67M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$6.23M |
| 4 |
DWA
Dorsey Wright & Associates
Pasadena,
California
|
-$5.17M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.91M |
ADAP Hedge Fund Activity: Q4 2018 in Review
80 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2018, worth a combined $397M — down 55% from $888M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ADAP and 14 opened new positions — a net loss of 13 holders — while 24 trimmed existing stakes and 27 added.
The largest buyer was Matrix Capital Management Company, adding an estimated $50.1M. The largest seller was Frontier Capital Management, exiting entirely with an estimated $9.47M sold.
- 80 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2018, down from 93 in Q3 2018.
- Funds reported $397M of Adaptimmune Therapeutics stock for Q4 2018, down 55% quarter-over-quarter.
- 14 funds opened new Adaptimmune Therapeutics positions in Q4 2018 and 27 closed out, a net change of -13 holders.
- The largest Adaptimmune Therapeutics buyer in Q4 2018 was Matrix Capital Management Company, an estimated $50.1M added.
- The largest Adaptimmune Therapeutics seller in Q4 2018 was Frontier Capital Management, an estimated $9.47M sold.
Based on aggregated 13F filings for Q4 2018.